Skip to main content
. 2018 Oct 16;9(5):987–1002. doi: 10.1002/jcsm.12354

Figure 7.

Figure 7

Inhibition of ERK–MAPK does not protect against LCM mediated loss of myotube diameter despite promoting protein synthesis. (A) Myotube diameter analysis of Control Media + Vehicle, Control Media + PD98059, LCM + Vehicle, and LCM + PD98059. (B) ERK MAPK phosphorylation relative to total protein content following 18 h of Control Media + Vehicle, Control Media + PD98059, LCM + Vehicle, and LCM + PD98059 treatment. (C) Puromycin incorporation for groups Control Media + Vehicle, Control Media + PD98059, LCM + Vehicle, and LCM + PD98059 after 30 min puromycin treatment following 18 h of treatments. (D) Protein ubiquitination following 18 h of Control Media + Vehicle, Control Media + PD98059, LCM + Vehicle, and LCM + PD98059 treatment. (E) Protein content of p‐4EBP1 relative to total 4EBP1, Deptor, p‐FOXO3 relative to total FOXO3, and p‐FOXO1 content relative to total FOXO1 following 18 h of Control Media + Vehicle, Control Media + PD98059, LCM + Vehicle, and LCM + PD98059 treatment. (F) Atrogin‐1 and MuRF‐1 mRNA content following 18 h of Control Media + Vehicle, Control Media + PD98059, LCM + Vehicle, and LCM + PD98059 treatment. All measured in C2C12 myotubes and normalized to and Ponceau S. Data are mean ± SEM. (G) Representative micrograph and immunoblot images for each protein of interest taken in order from same membrane. N of 6 was utilized for each group. Lettering denotes statistical significance (means that do not share the same letter are statistically different) at an alpha set at P < 0.05. ME indicates statistical Main Effect of indicated factor(s).